Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.Amna Ibrahim, Richard Pazdur, Yung Hsieh et al.|PubMed|2003Cited by 198
First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast CancerGideon M. Blumenthal, Richard Pazdur, Nancy S. Scher et al.|Clinical Cancer Research|2013Cited by 120
FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast CancerLynn Howie, Julia A. Beaver, Nancy S. Scher et al.|Clinical Cancer Research|2018Cited by 68
U.S. Food and Drug Administration Drug Approval Summaries: Imatinib Mesylate, Mesna Tablets, and Zoledronic AcidMartin H. Cohen, Richard Pazdur, Ramzi Dagher et al.|The Oncologist|2002Cited by 56
A population pharmacokinetic model for zoledronic acid (ZOMETA) in patients with bone metastasesB Booth, Jogarao Gobburu, Atiqur Rahman et al.|Clinical Pharmacology & Therapeutics|2003Cited by 3